103 related articles for article (PubMed ID: 26986816)
21. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
23. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
24. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
26. 131I effective half-life (Teff) for patients with thyroid cancer.
Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
[TBL] [Abstract][Full Text] [Related]
27. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
28. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
29. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
30. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
31. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
32. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
33. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
34. Relationship between estimated glomerular filtration rate and biological half-life of 131I. Retrospective analysis in patients with differentiated thyroid carcinoma.
Vogel K; Opfermann T; Wiegand S; Biermann J; Busch M; Winkens T; Freesmeyer M
Nuklearmedizin; 2013; 52(5):164-9. PubMed ID: 23821288
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
36. The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131.
Dardano A; Ballardin M; Caraccio N; Boni G; Traino C; Mariani G; Ferdeghini M; Barale R; Monzani F
Thyroid; 2012 Mar; 22(3):318-24. PubMed ID: 22181338
[TBL] [Abstract][Full Text] [Related]
37. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
38. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
39. Thyroid carcinoma with high levels of function: treatment with (131)I.
Sisson JC; Carey JE
J Nucl Med; 2001 Jun; 42(6):975-83. PubMed ID: 11390565
[TBL] [Abstract][Full Text] [Related]
40. The evolving use of radioiodine therapy in differentiated thyroid cancer.
Mayson SE; Yoo DC; Gopalakrishnan G
Oncology; 2015; 88(4):247-56. PubMed ID: 25503797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]